Source comparison
Clinical Evidence: Head-to-Head Comparison
No published randomized controlled trial has directly compared BPC-157 to PRP in human subjects. The available evidence comes from separate study populations and animal models. A 2020 meta-analysis in the American Journal of Sports Medicine reviewed 52 PRP tri
This comparison does not assign a generated winner or score.
- No published randomized controlled trial has directly compared BPC-157 to PRP in human subjects. The available evidence comes from separate study populations and animal models. A 2020 meta-analysis in the American Journal of Sports Medicine reviewed 52 PRP trials for tendinopathy and found moderate-quality evidence supporting pain reduction and functional improvement, with effect sizes ranging from 0.42 to 0.68 depending on injection protocol and platelet concentration. The AAOS (American Academy of Orthopaedic Surgeons) gives PRP a 'moderate' recommendation for lateral epicondylitis based on this body of evidence.
- BPC-157 evidence is almost entirely preclinical. The peptide has shown promise in rat models for Achilles tendon healing, ligament repair, and muscle regeneration, but no Phase III human trials have been published. A 2018 study in the Journal of Physiology and Pharmacology found that BPC-157 accelerated healing in surgically transected rat Achilles tendons, with biomechanical strength testing showing 74% recovery of intact tendon strength at 14 days versus 31% in controls. These results are compelling in controlled animal studies but haven't been replicated in human clinical populations.
- The regulatory distinction matters. PRP is FDA-cleared as an autologous blood product and widely available through orthopedic and sports medicine clinics. BPC-157 is not FDA-approved for any indication. It exists in a regulatory gray area as a research compound available through compounding pharmacies or peptide research suppliers. Our experience shows that patients seeking BPC-157 typically do so after PRP has been attempted without sufficient improvement, or when cost and accessibility barriers make PRP impractical.